|
Originally published In Press as doi:10.1074/jbc.M006287200 on August 30, 2000
J. Biol. Chem., Vol. 275, Issue 47, 36590-36595, November 24, 2000
Activation of Insulin Signal Transduction Pathway and
Anti-diabetic Activity of Small Molecule Insulin Receptor
Activators*
Sajjad A.
Qureshi §,
Victor
Ding §,
Zhihua
Li ,
Deborah
Szalkowski ,
Dawn E.
Biazzo-Ashnault ,
Dan
Xie ,
Richard
Saperstein¶,
Edward
Brady¶,
Su
Huskey ,
Xiaolan
Shen**,
Kun
Liu ,
Libo
Xu ,
Gino M.
Salituro§§,
James
V.
Heck ,
David E.
Moller ,
A. Brian
Jones , and
Bei B.
Zhang ¶¶
From the Departments of Molecular Endocrinology,
¶ Pharmacology, Drug Metabolism, ** Comparative Medicine,
§§ Natural Product Drug Discovery, and
 Medicinal Chemistry, Merck Research
Laboratories, Rahway, New Jersey 07065
We recently described the identification of a
non-peptidyl fungal metabolite (L-783,281, compound
1), which induced activation of human insulin receptor (IR) tyrosine
kinase and mediated insulin-like effects in cells, as well as decreased
blood glucose levels in murine models of Type 2 diabetes (Zhang, B.,
Salituro, G., Szalkowski, D., Li, Z., Zhang, Y., Royo, I., Vilella, D.,
Diez, M. T., Pelaez, F., Ruby, C., Kendall, R. L., Mao, X.,
Griffin, P., Calaycay, J., Zierath, J. R., Heck, J. V.,
Smith, R. G. & Moller, D. E. (1999) Science 284, 974-977). Here we report the characterization of an active
analog (compound 2) with enhanced IR kinase activation potency and
selectivity over related receptors (insulin-like growth factor I
receptor, epidermal growth factor receptor, and platelet-derived growth
factor receptor). The IR activators stimulated tyrosine kinase
activity of partially purified native IR and recombinant IR tyrosine
kinase domain. Administration of the IR activators to mice was
associated with increased IR tyrosine kinase activity in liver.
In vivo oral treatment with compound 2 resulted in
significant glucose lowering in several rodent models of diabetes. In
db/db mice, oral administration of compound 2 elicited significant
correction of hyperglycemia. In a streptozotocin-induced diabetic mouse
model, compound 2 potentiated the glucose-lowering effect of insulin. In normal rats, compound 2 improved oral glucose tolerance with significant reduction in insulin release following glucose challenge. A
structurally related inactive analog (compound 3) was not effective on
insulin receptor activation or glucose lowering in db/db mice. Thus,
small molecule IR activators exert insulin mimetic and sensitizing effects in cells and in animal models of diabetes. These results have
implications for the future development of new therapies for diabetes mellitus.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this paper.
¶¶
To whom correspondence and reprint requests should be
addressed: R80W250, Merck Research Laboratories, P. O. Box 2000, 126 E. Lincoln Ave., Rahway, NJ 07065. E-mail:
bei_zhang@merck.com.
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. A. Velliquette, J. E. Friedman, J. Shao, B. B. Zhang, and P. Ernsberger
Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor {gamma} Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X
J. Pharmacol. Exp. Ther.,
July 1, 2005;
314(1):
422 - 430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Z. Strowski, Z. Li, D. Szalkowski, X. Shen, X.-M. Guan, S. Juttner, D. E. Moller, and B. B. Zhang
Small-Molecule Insulin Mimetic Reduces Hyperglycemia and Obesity in a Nongenetic Mouse Model of Type 2 Diabetes
Endocrinology,
November 1, 2004;
145(11):
5259 - 5268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Li, N. D. Covino, E. G. Stein, J. H. Till, and S. R. Hubbard
Structural and Biochemical Evidence for an Autoinhibitory Role for Tyrosine 984 in the Juxtamembrane Region of the Insulin Receptor
J. Biol. Chem.,
July 3, 2003;
278(28):
26007 - 26014.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Li, J. F. Youngren, A. Dunaif, I. D. Goldfine, B. A. Maddux, B. B. Zhang, and J. L. Evans
Decreased Insulin Receptor (IR) Autophosphorylation in Fibroblasts from Patients with PCOS: Effects of Serine Kinase Inhibitors and IR Activators
J. Clin. Endocrinol. Metab.,
September 1, 2002;
87(9):
4088 - 4093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Lee
Functional Genomics and Cardiovascular Drug Discovery
Circulation,
September 18, 2001;
104(12):
1441 - 1446.
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|